157 related articles for article (PubMed ID: 32478898)
21. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
22. Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk.
Viola F; Lin-Schmidt X; Bhamidipati C; Haverstick DM; Walker WF; Ailawadi G; Lawrence MB
Thromb Res; 2016 Feb; 138():96-102. PubMed ID: 26688324
[TBL] [Abstract][Full Text] [Related]
23. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
24. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography.
Khurana S; Mattson JC; Westley S; O'Neill WW; Timmis GC; Safian RD
J Lab Clin Med; 1997 Oct; 130(4):401-11. PubMed ID: 9358079
[TBL] [Abstract][Full Text] [Related]
25. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
26. Cold storage of platelets in platelet additive solution maintains mitochondrial integrity by limiting initiation of apoptosis-mediated pathways.
Reddoch-Cardenas KM; Peltier GC; Chance TC; Nair PM; Meledeo MA; Ramasubramanian AK; Cap AP; Bynum JA
Transfusion; 2021 Jan; 61(1):178-190. PubMed ID: 33294977
[TBL] [Abstract][Full Text] [Related]
27. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
28. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
29. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of fibrinolysis by gel-filtered platelets and its quenching by cytochalasin B and GPIIb/IIIa antagonists.
Hoki S; Suzuki Y; Umemura K; Urano T
Pharmacol Rep; 2009; 61(5):877-84. PubMed ID: 19904011
[TBL] [Abstract][Full Text] [Related]
31. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
[TBL] [Abstract][Full Text] [Related]
32. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
[TBL] [Abstract][Full Text] [Related]
33. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.
Salanova B; Choi M; Rolle S; Wellner M; Luft FC; Kettritz R
J Biol Chem; 2007 Sep; 282(38):27960-9. PubMed ID: 17644514
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
35. Use of thromboelastography PlateletMapping to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome.
James K; Bertoja E; O'Beirne J; Mallett S
Liver Transpl; 2010 Jan; 16(1):38-41. PubMed ID: 20035517
[TBL] [Abstract][Full Text] [Related]
36. Hemostatic potential of cold-stored non-leukoreduced whole blood over time: An assessment of platelet function and thrombin generation for optimal shelf life.
Assen S; Cardenas J; George M; Wang YW; Wade CE; Meyer D; Cotton BA
J Trauma Acute Care Surg; 2020 Sep; 89(3):429-434. PubMed ID: 32467473
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
38. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
Fisher I; Robinson P; Ritter JM
Br J Clin Pharmacol; 1999 Aug; 48(2):197-9. PubMed ID: 10417496
[TBL] [Abstract][Full Text] [Related]
39. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
40. Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb.
Naimushin YA; Mazurov AV
Platelets; 2004 Nov; 15(7):419-25. PubMed ID: 15745313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
